C4 Therapeutics (CCCC) Assets Average (2020 - 2025)
Historic Assets Average for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to $281.0 million.
- C4 Therapeutics' Assets Average fell 2577.26% to $281.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.0 million, marking a year-over-year decrease of 2577.26%. This contributed to the annual value of $363.0 million for FY2024, which is 1006.3% down from last year.
- Per C4 Therapeutics' latest filing, its Assets Average stood at $281.0 million for Q3 2025, which was down 2577.26% from $308.0 million recorded in Q2 2025.
- C4 Therapeutics' Assets Average's 5-year high stood at $518.2 million during Q3 2021, with a 5-year trough of $281.0 million in Q3 2025.
- In the last 5 years, C4 Therapeutics' Assets Average had a median value of $387.4 million in 2024 and averaged $408.0 million.
- In the last 5 years, C4 Therapeutics' Assets Average surged by 6124.78% in 2021 and then tumbled by 2577.73% in 2023.
- C4 Therapeutics' Assets Average (Quarter) stood at $507.3 million in 2021, then dropped by 12.06% to $446.1 million in 2022, then fell by 20.49% to $354.7 million in 2023, then rose by 2.28% to $362.8 million in 2024, then decreased by 22.55% to $281.0 million in 2025.
- Its Assets Average was $281.0 million in Q3 2025, compared to $308.0 million in Q2 2025 and $334.6 million in Q1 2025.